Malaysian Genomics Resource Centre Bhd (XKLS:0155) Beta: 0.6074 (As of Jun. 24, 2026)


XKLS:0155 Malaysian Genomics Resource Centre Bhd XKLS:0155
47 GF Score
Price RM0.27
GF Value RM0.30
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Malaysian Genomics Resource Centre Bhd Beta?

Malaysian Genomics Resource Centre Bhd XKLS:0155 +1.89% 47 Beta is 0.6074 as of Jun. 24, 2026. GuruFocus rates XKLS:0155 with a GF Score™ of 47/100 and a GF Value™ of RM0.30 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Malaysian Genomics Resource Centre Bhd's Beta is 0.6074.


Malaysian Genomics Resource Centre Bhd  (XKLS:0155) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Malaysian Genomics Resource Centre Bhd Beta Related Terms


Malaysian Genomics Resource Centre Bhd Beta Historical Data

* Premium members only.

The historical data trend for Malaysian Genomics Resource Centre Bhd's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malaysian Genomics Resource Centre Bhd Beta Chart

Malaysian Genomics Resource Centre Bhd Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 1.71 0.47 -0.46 1.49

Malaysian Genomics Resource Centre Bhd Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 1.01 1.14 1.49 1.02

XKLS:0155 vs TMO, DHR, IDXX: Beta Comparison

For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Malaysian Genomics Resource Centre Bhd Beta vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's Beta distribution charts can be found below:

* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's Beta falls into.


XKLS:0155
47GF Score
Malaysian Genomics Resource Centre Bhd XKLS:0155
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malaysian Genomics Resource Centre Bhd Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.6074 mean?
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a Beta of 0.6074 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Malaysian Genomics Resource Centre Bhd and its competitors.
Is Malaysian Genomics Resource Centre Bhd's Beta too high?
Malaysian Genomics Resource Centre Bhd's current Beta is 0.6074. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's Beta compare to TMO and DHR?
Malaysian Genomics Resource Centre Bhd's Beta of 0.6074 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Diagnostics & Research company?
A good Beta depends on the Medical Diagnostics & Research industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Malaysian Genomics Resource Centre Bhd and its competitors. Malaysian Genomics Resource Centre Bhd's current Beta is 0.6074. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.30, compared to a current price of RM0.27 — trading 10% below its estimated fair value. The current Beta is 0.6074. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current Beta is 0.6074 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?

Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be undervalued. The current stock price of RM0.27 is trading 10% below its estimated GF Value™ of RM0.30. GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:0155:

  • Beta: 0.6074
  • GF Value™: RM0.30 vs. price of RM0.27 (10% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Malaysian Genomics Resource Centre Bhd Business Description

Address Jalan Teknologi 3/6, 8F, Taman Sains Selangor 1, Kota Damansara (PJU5), Petaling Jaya, SGR, MYS, 47810
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
47GF Score

Get the complete analysis for XKLS:0155

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.27
Price
RM0.30
GF Value